NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.

Andrew E SloanKathryn WinterMark R Gilbert Kenneth D AldapeSerah ChoiPatrick Yung WenNicholas ButowskiFabio M IwamotoRaju R RavalAlfredo D VoloschinCarlos Kamiya-MatsuokaMinhee WonMinesh P Mehta

Published in: Neuro-oncology (2024)

IPI and NIVO are safe and tolerable with toxicities similar to those noted with other cancers when given in combination with adjuvant TMZ for newly diagnosed GBM. Combination IPI+NIVO is not substantially more toxic than single agents. These results support a subsequent efficacy trial to test the combination of ICIs in a phase II/III for patients with newly diagnosed GBM.

Keyphrases

newly diagnosed
phase ii
clinical trial
open label
phase iii
early stage
randomized controlled trial
placebo controlled